

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



INNOVATIVE PHARMACEUTICAL BIOTECH LIMITED
領航醫藥及生物科技有限公司

(Incorporated in the Cayman Islands and continued in Bermuda with limited liability)

(Stock Code: 399)

TRADING SUSPENSION

At the request of Innovative Pharmaceutical Biotech Limited (the “**Company**”), trading in the shares of the Company on The Stock Exchange of Hong Kong Limited has been suspended with effect from 30 March 2016 (Wednesday) at 9:00 a.m. pending the release of an announcement in relation to a capital injection agreement which will constitute a notifiable transaction of the Company.

By order of the Board
Innovative Pharmaceutical Biotech Limited
Tang Rong
Executive Director

Hong Kong, 30 March 2016

As at the date of this announcement, the board of directors of the Company comprises Ms. Jiang Nian (chairman & non-executive director), Mr. Gao Yuan Xing (executive director), Mr. Tang Rong (executive director), Ms. Wu Yanmin (non-executive director), Ms. Xiao Yan (non-executive director), Ms. Chen Weijun (independent non-executive director), Dr. Zhang Zhihong (independent non-executive director) and Mr. Wang Rongliang (independent non-executive director).